Blue Water Vaccines Key Executives
This section highlights Blue Water Vaccines's key executives, including their titles and compensation details.
Find Contacts at Blue Water Vaccines
(Showing 0 of )
Blue Water Vaccines Earnings
This section highlights Blue Water Vaccines's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Financial Statements
Access annual & quarterly financial statements for Blue Water Vaccines, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|
| Revenue | $- | $- | $- | $- |
| Cost of Revenue | $- | $- | $- | $- |
| Gross Profit | $- | $- | $- | $- |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $4.13M | $1.33M | $524.91K | $60.17K |
| General and Administrative Expenses | $9.35M | $2.09M | $1.10M | $820.06K |
| Selling and Marketing Expenses | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $9.35M | $2.09M | $1.10M | $820.06K |
| Other Expenses | $- | $- | $- | $- |
| Operating Expenses | $13.48M | $3.42M | $1.62M | $880.23K |
| Cost and Expenses | $13.48M | $3.42M | $1.62M | $880.23K |
| Interest Income | $- | $- | $22.60K | $58.32K |
| Interest Expense | $- | $- | $- | $- |
| Depreciation and Amortization | $-61.41K | $4.89K | $3.06K | $573 |
| EBITDA | $-13.48M | $-3.41M | $-1.62M | $-879.66K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-13.48M | $-3.42M | $-1.62M | $-880.23K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $61.41K | $- | $22.60K | $58.32K |
| Income Before Tax | $-13.42M | $-3.42M | $-1.60M | $-821.91K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $-129.57K | $- | $-22.60K | $-58.32K |
| Net Income | $-13.29M | $-3.42M | $-1.58M | $-763.60K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-1.08 | $-0.31 | $-0.14 | $-0.07 |
| EPS Diluted | $-1.08 | $-0.31 | $-0.14 | $-0.07 |
| Weighted Average Shares Outstanding | 12.27M | 10.91M | 11.05M | 11.05M |
| Weighted Average Shares Outstanding Diluted | 12.27M | 10.91M | 11.05M | 11.05M |
| SEC Filing | Source | Source | Source | Source |
| Breakdown | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $219.24K | $846.85K | $1.08M | $1.21M | $1.18M | $1.29M | $455.09K | $437.33K | $269.93K | $529.54K | $88.24K | $101.65K |
| General and Administrative Expenses | $4.27M | $2.30M | $1.77M | $2.04M | $2.69M | $3.00M | $1.62M | $766.03K | $826.00K | $262.73K | $237.54K | $303.75K |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $4.27M | $2.30M | $1.77M | $2.04M | $2.69M | $3.00M | $1.62M | $766.03K | $826.00K | $262.73K | $237.54K | $303.75K |
| Other Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Operating Expenses | $4.49M | $3.15M | $2.85M | $3.25M | $3.87M | $4.29M | $2.07M | $1.20M | $1.10M | $792.27K | $325.78K | $405.40K |
| Cost and Expenses | $4.49M | $3.15M | $2.85M | $3.25M | $3.87M | $4.29M | $2.07M | $1.20M | $1.10M | $792.27K | $325.78K | $405.40K |
| Interest Income | $- | $214 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $998 |
| Interest Expense | $269.10K | $214.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $998 |
| Depreciation and Amortization | $1.62K | $1.57K | $83 | $-26.19K | $-3.07K | $-28.54K | $1.30K | $1.15K | $1.26K | $1.25K | $1.23K | $1.01K |
| EBITDA | $-4.49M | $-3.15M | $-2.85M | $-3.25M | $-3.87M | $-4.29M | $-2.07M | $-1.20M | $-1.09M | $-791.03K | $-324.55K | $-404.39K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-4.49M | $-6.65M | $-2.85M | $-3.25M | $-3.87M | $-4.29M | $-2.07M | $-1.20M | $-1.10M | $-792.27K | $-325.78K | $-405.40K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $-858.83K | $-3.72M | $1.61K | $28.04K | $3.07K | $30.30K | $- | $- | $- | $- | $- | $998 |
| Income Before Tax | $-5.35M | $-6.87M | $-2.85M | $-3.22M | $-3.87M | $-4.26M | $-2.07M | $-1.20M | $-1.10M | $-792.27K | $-325.78K | $-404.40K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $269.10K | $214.00K | $-1.61K | $-56.07K | $-7.99K | $-60.61K | $- | $- | $- | $- | $- | $- |
| Net Income | $-5.35M | $-6.87M | $-2.85M | $-3.16M | $-3.86M | $-4.20M | $-2.07M | $-1.20M | $-1.10M | $-792.27K | $-325.78K | $-404.40K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-0.31 | $-0.43 | $-0.18 | $-0.26 | $-0.27 | $-0.35 | $-0.33 | $-0.11 | $-0.10 | $-0.07 | $-0.03 | $-0.04 |
| EPS Diluted | $-0.31 | $-0.43 | $-0.18 | $-0.26 | $-0.27 | $-0.35 | $-0.33 | $-0.11 | $-0.10 | $-0.07 | $-0.03 | $-0.04 |
| Weighted Average Shares Outstanding | 17.52M | 15.91M | 15.91M | 12.27M | 14.34M | 12.00M | 6.34M | 10.91M | 11.05M | 11.05M | 11.05M | 11.05M |
| Weighted Average Shares Outstanding Diluted | 17.52M | 15.91M | 15.91M | 12.27M | 14.34M | 12.00M | 6.34M | 11.05M | 11.05M | 11.05M | 11.05M | 11.05M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|
| Cash and Cash Equivalents | $25.75M | $1.93M | $4.31M | $6.05M |
| Short Term Investments | $- | $- | $- | $- |
| Cash and Short Term Investments | $25.75M | $1.93M | $4.31M | $6.05M |
| Net Receivables | $- | $- | $- | $8.33K |
| Inventory | $- | $-152.52K | $277.56K | $-0 |
| Other Current Assets | $505.08K | $1.14M | $287.66K | $8.34K |
| Total Current Assets | $26.26M | $3.07M | $4.60M | $6.06M |
| Property Plant Equipment Net | $14.09K | $11.50K | $15.67K | $6.93K |
| Goodwill | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- |
| Other Non-Current Assets | $38.62K | $- | $199.93K | $15.00K |
| Total Non-Current Assets | $52.71K | $11.50K | $215.60K | $21.93K |
| Other Assets | $- | $- | $- | $- |
| Total Assets | $26.31M | $3.08M | $4.81M | $6.08M |
| Account Payables | $1.50M | $582.61K | $68.67K | $18.38K |
| Short Term Debt | $- | $- | $- | $- |
| Tax Payables | $177.60K | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- |
| Other Current Liabilities | $2.25M | $1.06M | $- | $57.38K |
| Total Current Liabilities | $3.92M | $1.64M | $68.67K | $75.76K |
| Long Term Debt | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- |
| Total Non-Current Liabilities | $1.50M | $- | $9.64K | $6.86K |
| Other Liabilities | $-1.50M | $- | $- | $-0 |
| Total Liabilities | $3.92M | $1.64M | $78.31K | $82.62K |
| Preferred Stock | $- | $11 | $11 | $11 |
| Common Stock | $157 | $32 | $32 | $32 |
| Retained Earnings | $-19.38M | $-5.96M | $-2.54M | $-939.87K |
| Accumulated Other Comprehensive Income Loss | $- | $- | $- | $- |
| Other Total Stockholders Equity | $41.76M | $7.40M | $7.27M | $6.94M |
| Total Stockholders Equity | $22.39M | $1.45M | $4.73M | $6.00M |
| Total Equity | $22.39M | $1.45M | $4.73M | $6.00M |
| Total Liabilities and Stockholders Equity | $26.31M | $3.08M | $4.81M | $6.08M |
| Minority Interest | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $26.31M | $3.08M | $4.81M | $6.08M |
| Total Investments | $- | $- | $- | $- |
| Total Debt | $- | $- | $- | $- |
| Net Debt | $-25.75M | $-1.93M | $-4.31M | $-6.05M |
Balance Sheet Charts
| Breakdown | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | December 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $7.65M | $9.22M | $20.26M | $25.75M | $29.14M | $22.24M | $18.61M | $1.93M | $2.74M | $4.31M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $7.65M | $9.22M | $20.26M | $25.75M | $29.14M | $22.24M | $18.61M | $1.93M | $2.74M | $4.31M |
| Net Receivables | $- | $325.05K | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $1.42M | $1.17M | $-70.30K | $- | $- | $-20.36K | $- | $-152.52K | $- | $- |
| Other Current Assets | $467.74K | $685.41K | $2.22M | $505.08K | $914.81K | $1.27M | $493.32K | $1.14M | $621.54K | $287.66K |
| Total Current Assets | $9.54M | $11.41M | $22.47M | $26.26M | $30.05M | $23.51M | $19.10M | $3.07M | $3.36M | $4.60M |
| Property Plant Equipment Net | $12.50K | $14.12K | $14.21K | $14.09K | $15.93K | $17.78K | $15.40K | $11.50K | $11.93K | $15.67K |
| Goodwill | $- | $17.89M | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $17.91M | $17.91K | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $17.91M | $17.91M | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $421.61K | $421.61K | $15.50K | $38.62K | $93.94K | $101.56K | $217.09K | $- | $46.23K | $199.93K |
| Total Non-Current Assets | $18.34M | $18.34M | $29.71K | $52.71K | $109.88K | $119.34K | $232.49K | $11.50K | $58.16K | $215.60K |
| Other Assets | $- | $-0 | $-0 | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $27.88M | $29.75M | $22.50M | $26.31M | $30.16M | $23.63M | $19.34M | $3.08M | $3.42M | $4.81M |
| Account Payables | $3.18M | $2.08M | $1.50M | $1.50M | $834.31K | $972.97K | $907.54K | $582.61K | $263.86K | $68.67K |
| Short Term Debt | $12.92M | $8.62M | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Payables | $- | $89.60K | $26.20K | $177.60K | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $1.54M | $1.42M | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Liabilities | $10.46K | $-75.52K | $1.28M | $2.25M | $3.60M | $2.09M | $1.89M | $1.06M | $532.11K | $- |
| Total Current Liabilities | $17.65M | $12.13M | $2.81M | $3.92M | $4.43M | $3.06M | $2.80M | $1.64M | $795.98K | $68.67K |
| Long Term Debt | $- | $4.54M | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $9.64K |
| Total Non-Current Liabilities | $- | $4.54M | $1.50M | $1.50M | $834.31K | $972.97K | $907.54K | $582.61K | $- | $9.64K |
| Other Liabilities | $- | $- | $-1.50M | $-1.50M | $-834.31K | $-972.97K | $-907.54K | $-582.61K | $- | $- |
| Total Liabilities | $17.65M | $16.67M | $2.81M | $3.92M | $4.43M | $3.06M | $2.80M | $1.64M | $795.98K | $78.31K |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $11 | $11 | $11 |
| Common Stock | $183 | $169 | $164 | $157 | $147 | $122 | $110 | $32 | $32 | $32 |
| Retained Earnings | $-34.44M | $-29.09M | $-22.22M | $-19.38M | $-16.16M | $-12.29M | $-8.03M | $-5.96M | $-4.75M | $-2.54M |
| Accumulated Other Comprehensive Income Loss | $- | $- | $- | $- | $- | $- | $- | $-11 | $- | $- |
| Other Total Stockholders Equity | $44.67M | $42.16M | $41.92M | $41.76M | $41.89M | $32.87M | $24.56M | $7.40M | $7.38M | $7.27M |
| Total Stockholders Equity | $10.24M | $13.08M | $19.69M | $22.39M | $25.73M | $20.57M | $16.53M | $1.45M | $2.63M | $4.73M |
| Total Equity | $10.24M | $13.08M | $19.69M | $22.39M | $25.73M | $20.57M | $16.53M | $- | $- | $- |
| Total Liabilities and Stockholders Equity | $27.88M | $29.75M | $22.50M | $26.31M | $30.16M | $23.63M | $19.34M | $3.08M | $3.42M | $4.81M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $27.88M | $29.75M | $22.50M | $26.31M | $30.16M | $23.63M | $19.34M | $3.08M | $3.42M | $4.81M |
| Total Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Debt | $12.92M | $13.16M | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Debt | $5.27M | $3.94M | $-20.26M | $-25.75M | $-29.14M | $-22.24M | $-18.61M | $-1.93M | $-2.74M | $-4.31M |
Annual Cash Flow
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|
| Net Income | $-13.42M | $-3.42M | $-1.60M | $-821.91K |
| Depreciation and Amortization | $6.75K | $4.89K | $3.06K | $573 |
| Deferred Income Tax | $- | $- | $134 | $4 |
| Stock Based Compensation | $1.97M | $130.14K | $334.84K | $3.27K |
| Change in Working Capital | $2.54M | $1.21M | $-468.56K | $-7.05K |
| Accounts Receivables | $-23 | $-115 | $-36 | $-8 |
| Inventory | $23 | $115 | $36 | $8 |
| Accounts Payables | $1.09M | $336.71K | $50.29K | $18.38K |
| Other Working Capital | $1.44M | $877.91K | $-518.86K | $-25.43K |
| Other Non Cash Items | $202.51K | $23.44K | $-134 | $-4 |
| Net Cash Provided by Operating Activities | $-8.70M | $-2.04M | $-1.73M | $-825.13K |
| Investments in Property Plant and Equipment | $-9.34K | $-1.92K | $-11.79K | $-4.50K |
| Acquisitions Net | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $-9.34K | $-1.92K | $-11.79K | $-4.50K |
| Debt Repayment | $- | $- | $- | $- |
| Common Stock Issued | $34.87M | $- | $- | $- |
| Common Stock Repurchased | $-566.81K | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- |
| Other Financing Activities | $32.53M | $-334.19K | $- | $6.88M |
| Net Cash Used Provided by Financing Activities | $32.53M | $-334.19K | $- | $6.88M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- |
| Net Change in Cash | $23.82M | $-2.38M | $-1.74M | $6.05M |
| Cash at End of Period | $25.75M | $1.93M | $4.31M | $6.05M |
| Cash at Beginning of Period | $1.93M | $4.31M | $6.05M | $- |
| Operating Cash Flow | $-8.70M | $-2.04M | $-1.73M | $-825.13K |
| Capital Expenditure | $-9.34K | $-1.92K | $-11.79K | $-4.50K |
| Free Cash Flow | $-8.71M | $-2.05M | $-1.74M | $-829.63K |
Cash Flow Charts
| Breakdown | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-5.35M | $-6.87M | $-2.85M | $-3.22M | $-3.87M | $-4.26M | $-2.07M | $-1.20M | $-1.10M | $-792.27K | $-325.78K | $-404.40K |
| Depreciation and Amortization | $1.62K | $1.57K | $1.70K | $1.85K | $1.84K | $1.76K | $1.30K | $1.15K | $1.26K | $1.25K | $1.23K | $1.01K |
| Deferred Income Tax | $856.75K | $- | $- | $- | $- | $- | $- | $-2.21M | $- | $- | $- | $- |
| Stock Based Compensation | $105.40K | $272.78K | $185.58K | $178.30K | $329.81K | $1.45M | $19.33K | $24.19K | $29.31K | $34.92K | $41.72K | $58.62K |
| Change in Working Capital | $973.39K | $927.21K | $-1.79M | $673 | $1.71M | $-336.42K | $1.16M | $480.17K | $334.88K | $373.30K | $26.28K | $77.35K |
| Accounts Receivables | $- | $34 | $-34 | $-1 | $-14 | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $-247.37K | $-52 | $-1.79M | $1 | $14 | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $990.64K | $641.72K | $-214.31K | $732.81K | $-130.66K | $139.94K | $351.82K | $201.83K | $147.93K | $-55.45K | $42.41K | $28.32K |
| Other Working Capital | $230.12K | $285.50K | $214.31K | $-732.14K | $1.84M | $-476.36K | $812.12K | $278.34K | $186.95K | $428.75K | $-16.13K | $49.03K |
| Other Non Cash Items | $369.39K | $3.88M | $-1.61K | $235.89K | $-3.07K | $-30.30K | $- | $2.24M | $- | $- | $- | $- |
| Net Cash Provided by Operating Activities | $-3.04M | $-1.78M | $-4.45M | $-2.80M | $-1.83M | $-3.18M | $-886.09K | $-674.40K | $-730.48K | $-382.81K | $-256.55K | $-267.42K |
| Investments in Property Plant and Equipment | $-51.74K | $-1.48K | $-1.82K | $5.19K | $- | $-4.14K | $-5.20K | $-1.92K | $- | $- | $- | $-3.85K |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $224.76K | $-10.03M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $173.01K | $-10.04M | $-1.82K | $5.19K | $- | $-4.14K | $-5.20K | $-1.92K | $- | $- | $- | $-3.85K |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $- | $- | $-45.67M | $9.15M | $7.32M | $18.40M | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $-25.53K | $-33.45K | $-567 | $- | $1.50M | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $1.30M | $-214.66K | $-48.95K | $-582.84K | $8.72M | $6.82M | $17.57M | $-137.21K | $-196.97K | $- | $- | $- |
| Net Cash Used Provided by Financing Activities | $1.30M | $-214.66K | $-48.95K | $-582.84K | $8.72M | $6.82M | $17.57M | $-137.21K | $-196.97K | $- | $- | $- |
| Effect of Forex Changes on Cash | $-3.78M | $- | $- | $-5.19K | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-1.57M | $-12.03M | $-4.50M | $-3.38M | $6.89M | $3.63M | $16.68M | $-813.54K | $-927.45K | $-382.81K | $-256.55K | $-271.28K |
| Cash at End of Period | $7.65M | $9.22M | $21.26M | $25.75M | $29.14M | $22.24M | $18.61M | $1.93M | $2.74M | $3.67M | $4.05M | $4.31M |
| Cash at Beginning of Period | $9.22M | $21.26M | $25.75M | $29.14M | $22.24M | $18.61M | $1.93M | $2.74M | $3.67M | $4.05M | $4.31M | $4.58M |
| Operating Cash Flow | $-3.04M | $-1.78M | $-4.45M | $-2.80M | $-1.83M | $-3.18M | $-886.09K | $-674.40K | $-730.48K | $-382.81K | $-256.55K | $-267.42K |
| Capital Expenditure | $-51.74K | $-1.48K | $-1.82K | $5.19K | $- | $-4.14K | $-5.20K | $-1.92K | $- | $- | $- | $-3.85K |
| Free Cash Flow | $-3.09M | $-1.78M | $-4.45M | $-2.80M | $-1.83M | $-3.19M | $-891.29K | $-676.33K | $-730.48K | $-382.81K | $-256.55K | $-271.28K |
Blue Water Vaccines, Inc., a biotechnology company, engages in the research and development of vaccines to prevent infectious diseases worldwide. The company's lead vaccine programs that are under preclinical development include BWV-101, an influenza vaccine; and BWV-102, a H1 pre-pandemic vaccine. It also has other pipeline under preclinical development comprising BWV-201, a streptococcus pneumoniae induced acute otitis media vaccine program; BWV-301, a norovirus-rotavirus vaccine program; and BWV-302, a norovirus-malaria vaccine program. The company was incorporated in 2018 and is based in Cincinnati, Ohio.
$0.18
Stock Price
$3.41M
Market Cap
12
Employees
Cincinnati, OH
Location
Revenue (FY )
$-
0.0% YoY
Net Income (FY )
$-
-288.9% YoY
EPS (FY )
$
-248.4% YoY
Free Cash Flow (FY )
$-
-325.6% YoY
Profitability
Gross Margin
-1927.9%
Net Margin
-63986.5%
ROE
-63.8%
ROA
-42.7%
Valuation
P/E Ratio
-0.09
P/S Ratio
57.95
EV/EBITDA
-0.24
Market Cap
$3.41M
Revenue & Net Income
Profit Margins
Cash Flow Summary
Operating Cash Flow
$-
-325.5% YoY
Free Cash Flow
$-
-325.6% YoY
Balance Sheet Summary
Total Assets
$-
752.9% YoY
Total Debt
$-
0.0% YoY
Shareholder Equity
$-
1276.4% YoY
Dividend Overview
No Dividend Data
Blue Water Vaccines, Inc. doesn't currently pay dividends.
Blue Water Vaccines Dividends
Explore Blue Water Vaccines's dividend history, including dividend yield, payout ratio, and historical payments.
Blue Water Vaccines News
Read the latest news about Blue Water Vaccines, including recent articles, headlines, and updates.
Onconetix™ Chief Executive Officer Dr. Neil J. Campbell Issues Letter to Shareholders
CINCINNATI, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: BWV) ("Onconetix" or the “Company”) today issued the following shareholder letter from the Company's Chief Executive Officer, Dr. Neil Campbell.
Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix™
Transaction strengthens commercial business with addition of diagnostics product and initial focus on prostate cancer Transaction strengthens commercial business with addition of diagnostics product and initial focus on prostate cancer
Blue Water Biotech Signs Non-Binding Term Sheet to Acquire a Commercial Stage Oncology Company
Transaction will Advance Company's Shift in Business Strategy Aligned with Life Sciences Industry Expertise of New Leadership Team Transaction will Advance Company's Shift in Business Strategy Aligned with Life Sciences Industry Expertise of New Leadership Team
Blue Water Biotech Announces It Has Regained Compliance with Nasdaq Listing Rule 5250(c)(1)
CINCINNATI, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (Nasdaq: BWV) ("BWB" or the “Company”) today announced that it has received a letter from the Nasdaq Stock Market, LLC ("Nasdaq") stating that the Company has regained compliance with the Nasdaq Stock Market, LLC Listing Rule 5250(c)(1) (the "Rule").
Blue Water Biotech Appoints Dr. Neil J. Campbell as President and CEO and Bruce Harmon as CFO
CINCINNATI, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (Nasdaq: BWV), which is focused on developing and commercializing transformational therapies to address significant global health challenges, today announced the appointments of Dr. Neil J. Campbell as President and CEO and Bruce Harmon as CFO, effective immediately.
Blue Water Biotech, Inc. Announces Notification From Nasdaq Related to Delayed Quarterly Report on Form 10-Q
CINCINNATI, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biotechnology and pharmaceutical company spanning multiple sectors, today announced that it received a delinquency notification letter (“Notice”) from the Listing Qualifications staff of the Nasdaq Stock Market LLC (“Nasdaq”) on August 22, 2023 due to the Company's non-compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the Company's failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2023 (the “Form 10 - Q”). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the “SEC”).
Blue Water Biotech Announces Closing of Warrant Exercise and Issuance of New Warrants in A Private Placement For $2.7 Million Gross Proceeds
CINCINNATI, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), today announced the closing of its previously announced exercise of certain existing warrants to purchase 2,486,214 shares of its common stock at a reduced exercise price of $1.09 per share, in exchange for new warrants as described below. The aggregate gross proceeds from the exercise of the existing warrants were approximately $2.7 million, before deducting placement agent fees and other offering expenses payable by the Company.
Blue Water Biotech Announces Exercise of Warrants and Issuance of New Warrants in A Private Placement For $2.7 Million Gross Proceeds
CINCINNATI, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. ("Blue Water" or the “Company”) (Nasdaq: BWV), today announced it has entered into a definitive agreement for the exercise of certain existing warrants to purchase 2,486,214 shares of its common stock at a reduced exercise price of $1.09 per share, in exchange for new warrants as described below. The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $2.7 million, before deducting placement agent fees and other offering expenses payable by the Company. The transaction is expected to close on or about August 2, 2023, subject to satisfaction of customary closing conditions.
Blue Water Biotech and Knipper Health Join Forces to Distribute Samples for ENTADFI® and ZONTIVITY® to Physicians
CINCINNATI, July 31, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology and pharmaceutical company focused on developing and commercializing transformational therapies to address significant health challenges globally, today announced an agreement with Knipper Health, Inc. (“Knipper Health”) to manage the inventory and distribution of product samples to sales representatives for ENTADFI® and ZONTIVITY®.
Blue Water Biotech Teams with UpScriptHealth to Launch Telemedicine Platform for Benign Prostatic Hyperplasia Asset, ENTADFI®
CINCINNATI, July 25, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology and pharmaceutical company focused on developing and commercializing transformational therapies to address significant health challenges globally, today announced an agreement with UpScriptHealth (“UpScript”) to generate a robust, online telemedicine platform to distribute Blue Water's benign prostatic hyperplasia (“BPH”) asset, ENTADFI®.
Blue Water Biotech Issues CEO Shareholder Letter Providing Update on Commercial Launch Activities
CINCINNATI, July 17, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology and pharmaceutical company focused on developing and commercializing transformational therapies to address significant health challenges globally, today issued the following letter to shareholders from its Chairman and Chief Executive Officer, Joseph Hernandez.
Blue Water Biotech Secures License from Ohio State Board of Pharmacy to Operate as Pharmaceutical Wholesaler for its FDA Approved Products
First state license is a key achievement as Blue Water continues to expand its business into commercial activities First state license is a key achievement as Blue Water continues to expand its business into commercial activities
Blue Water Biotech to Present Corporate Overview and ENTADFI® Launch Plan at the JMP Securities Life Sciences Conference in New York, NY
CINCINNATI, May 10, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biopharmaceutical company developing transformational therapies to address significant global health challenges, today announced that Blue Water management will present at the JMP Securities Life Sciences Conference at the New York Hilton Midtown on Monday, May 15th at 3:30pm EDT.
Blue Water Vaccines to Present at Biotech Showcase 2023 During the 41st Annual J.P. Morgan Healthcare Conference Week in San Francisco
CINCINNATI, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced that BWV management will present at the Biotech Showcase 2023 in San Francisco, California, happening during the 41st Annual J.P. Morgan Healthcare Conference. During the presentation, management will provide a corporate overview, recent milestones and execution, and company pipeline updates.
Blue Water Vaccines to Present Update on Novel, Live Attenuated, Intranasally Delivered Streptococcus pneumoniae Vaccine to Prevent Acute Otitis Media, Pneumococcal Pneumonia, and Invasive Pneumococcal Disease at the World Vaccine & Immunotherapy Congress West Coast 2022
CINCINNATI, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), today announced that Ali Fattom, Ph.D., will present at the World Vaccine & Immunotherapy Congress West Coast 2022 in San Diego, California on Thursday, December 1, 2022. Dr. Fattom will present an overview and current progress of BWV-201, a live attenuated, intranasally delivered, serotype independent Streptococcus pneumoniae vaccine candidate for the prevention of acute otitis media (“AOM”), pneumococcal pneumonia, and invasive pneumococcal disease.
Blue Water Vaccines to Present at World Vaccine Congress Europe 2022
CINCINNATI, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced that the Company will host a roundtable discussion and present at the World Vaccine Congress Europe 2022 in Barcelona, Spain.
Blue Water Vaccines to Present at The Universal Influenza Vaccines 2022 Conference in Oxford, United Kingdom
CINCINNATI, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced that scientists from its research partner, The University of Oxford, will present at The Universal Influenza Vaccines 2022 Conference in Oxford, United Kingdom on Monday, September 5th, 2022.
BWV Stock Soars as Blue Water Vaccines Explores Monkeypox Vaccine
Source: angellodeco / Shutterstock.com Blue Water Vaccines (NASDAQ: BWV ) stock is rocketing higher on Wednesday after the company announced it will explore the possibility of making a monkeypox vaccine. According to a press release from the company, it intends to use its norovirus shell and protrusion (S&P) virus-like particle (VLP) platform for this.
Blue Water Vaccines to Present at the JMP Securities Life Science Conference
CINCINNATI, June 06, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced that Joseph Hernandez, Chairman and Chief Executive Officer of BWV, will present at the JMP Securities Life Science Conference. Mr. Hernandez will present a corporate overview and update for BWV's vaccine candidate pipeline.
Blue Water Vaccines Inc. to Present at H.C. Wainwright Global Investment Conference
CINCINNATI, May 12, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced that Erin Henderson, Chief Business Officer of Blue Water Vaccines, will present at the H.C. Wainwright Global Investment Conference. The presentation will be available for on-demand webcast viewing starting on Wednesday, May 25, 2022, at 9:00am EDT.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for BWV.